Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Use of gemtuzumab ozogamicin in CBF-AML

Alan Burnett • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies Cytarabine Gemtuzumab ozogamicin

Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the clinical development of gemtuzumab ozogamicin, focusing on its use in core binding factor (CBF) acute myeloid leukemia (AML) and the remaining questions in this field. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Alan Burnett

2:32
ISAL session highlights: gemtuzumab & small molecule inhibitors with chemotherapy in AML and APL
Alan Burnett • 21 Mar 2023
3:14
Standard treatment of elderly patients with AML & evaluating IDH inhibitors in younger patients
Alan Burnett • 21 Mar 2023
11:06
The future treatment of acute leukemias: part I
Alan Burnett et al. • 18 Jun 2019
19:48
The future treatment of acute leukemias: part II
Alan Burnett et al. • 18 Jun 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals